SPOTLIGHT: Shareholders blast Dendreon


Angry shareholders have sued Dendreon, claiming that the company misrepresented its clinical data for Provenge and failed to provide clear guidance on when the FDA would make its decision on the prostate cancer drug. Several weeks ago the agency demanded more data on Provenge before it could be approved. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.